208 related articles for article (PubMed ID: 15215080)
21. Susceptibility and trailing growth of Candida albicans to fluconazole: results of a Korean multicentre study.
Lee MK; Kim HR; Kang JO; Kim MN; Kim EC; Kim JS; Kim JJ; Park YJ; Song W; Shin JH; Lee KM; Lee NY; Lee M; Lee WG; Lee CK; Lee HJ; Chang CL; Choi TY
Mycoses; 2007 Mar; 50(2):148-9. PubMed ID: 17305780
[TBL] [Abstract][Full Text] [Related]
22. Farnesol concentrations required to block germ tube formation in Candida albicans in the presence and absence of serum.
Mosel DD; Dumitru R; Hornby JM; Atkin AL; Nickerson KW
Appl Environ Microbiol; 2005 Aug; 71(8):4938-40. PubMed ID: 16085901
[TBL] [Abstract][Full Text] [Related]
23. Impact of brief exposure to antifungal agents on the post-antifungal effect and hemolysin activity of oral Candida albicans.
Ellepola AN; Khajah R; Jayatilake S; Samaranayake L; Sharma P; Khan Z
J Appl Oral Sci; 2015; 23(4):412-8. PubMed ID: 26398514
[TBL] [Abstract][Full Text] [Related]
24. Penetration of Candida biofilms by antifungal agents.
Al-Fattani MA; Douglas LJ
Antimicrob Agents Chemother; 2004 Sep; 48(9):3291-7. PubMed ID: 15328087
[TBL] [Abstract][Full Text] [Related]
25. Anaerobic growth of Candida albicans does not support biofilm formation under similar conditions used for aerobic biofilm.
Biswas SK; Chaffin WL
Curr Microbiol; 2005 Aug; 51(2):100-4. PubMed ID: 15991052
[TBL] [Abstract][Full Text] [Related]
26. Effect of farnesol on Candida dubliniensis biofilm formation and fluconazole resistance.
Jabra-Rizk MA; Shirtliff M; James C; Meiller T
FEMS Yeast Res; 2006 Nov; 6(7):1063-73. PubMed ID: 17042756
[TBL] [Abstract][Full Text] [Related]
27. Repurposing as a means to increase the activity of amphotericin B and caspofungin against Candida albicans biofilms.
Delattin N; De Brucker K; Vandamme K; Meert E; Marchand A; Chaltin P; Cammue BP; Thevissen K
J Antimicrob Chemother; 2014 Apr; 69(4):1035-44. PubMed ID: 24284780
[TBL] [Abstract][Full Text] [Related]
28. Activity and toxicity of farnesol towards Candida albicans are dependent on growth conditions.
Langford ML; Hasim S; Nickerson KW; Atkin AL
Antimicrob Agents Chemother; 2010 Feb; 54(2):940-2. PubMed ID: 19933803
[TBL] [Abstract][Full Text] [Related]
29. Biofilm formation by fluconazole-resistant Candida albicans strains is inhibited by fluconazole.
Bruzual I; Riggle P; Hadley S; Kumamoto CA
J Antimicrob Chemother; 2007 Mar; 59(3):441-50. PubMed ID: 17261564
[TBL] [Abstract][Full Text] [Related]
30. [In vitro susceptibility of vaginal Candida albicans to antifungal drugs in Abidjan (Ivory Coast)].
Djohan V; Angora KE; Vanga-Bosson AH; Konaté A; Kassi FK; Yavo W; Kiki-Barro PC; Menan H; Koné M
J Mycol Med; 2012 Jun; 22(2):129-33. PubMed ID: 23518014
[TBL] [Abstract][Full Text] [Related]
31. Antifungal potential of Sideroxylon obtusifolium and Syzygium cumini and their mode of action against Candida albicans.
Pereira JV; Freires IA; Castilho AR; da Cunha MG; Alves Hda S; Rosalen PL
Pharm Biol; 2016 Oct; 54(10):2312-9. PubMed ID: 26987037
[TBL] [Abstract][Full Text] [Related]
32. The inhibition of trans-cinnamaldehyde on the virulence of Candida albicans via enhancing farnesol secretion with low potential for the development of resistance.
Ying L; Mingzhu S; Mingju Y; Ye X; Yuechen W; Ying C; Bing G; Hongchun L; Zuobin Z
Biochem Biophys Res Commun; 2019 Aug; 515(4):544-550. PubMed ID: 31176484
[TBL] [Abstract][Full Text] [Related]
33. Multiple effects of green tea catechin on the antifungal activity of antimycotics against Candida albicans.
Hirasawa M; Takada K
J Antimicrob Chemother; 2004 Feb; 53(2):225-9. PubMed ID: 14688042
[TBL] [Abstract][Full Text] [Related]
34. Synergistic activity of lysozyme and antifungal agents against Candida albicans biofilms on denture acrylic surfaces.
Samaranayake YH; Cheung BP; Parahitiyawa N; Seneviratne CJ; Yau JY; Yeung KW; Samaranayake LP
Arch Oral Biol; 2009 Feb; 54(2):115-26. PubMed ID: 19038377
[TBL] [Abstract][Full Text] [Related]
35. Effect of farnesol on a mouse model of systemic candidiasis, determined by use of a DPP3 knockout mutant of Candida albicans.
Navarathna DH; Hornby JM; Krishnan N; Parkhurst A; Duhamel GE; Nickerson KW
Infect Immun; 2007 Apr; 75(4):1609-18. PubMed ID: 17283095
[TBL] [Abstract][Full Text] [Related]
36. Susceptibility of Candida albicans biofilms grown in a constant depth film fermentor to chlorhexidine, fluconazole and miconazole: a longitudinal study.
Lamfon H; Porter SR; McCullough M; Pratten J
J Antimicrob Chemother; 2004 Feb; 53(2):383-5. PubMed ID: 14729749
[TBL] [Abstract][Full Text] [Related]
37. Disruption of mitochondrial function in Candida albicans leads to reduced cellular ergosterol levels and elevated growth in the presence of amphotericin B.
Geraghty P; Kavanagh K
Arch Microbiol; 2003 Apr; 179(4):295-300. PubMed ID: 12640519
[TBL] [Abstract][Full Text] [Related]
38. Candida albicans biofilms produce antifungal-tolerant persister cells.
LaFleur MD; Kumamoto CA; Lewis K
Antimicrob Agents Chemother; 2006 Nov; 50(11):3839-46. PubMed ID: 16923951
[TBL] [Abstract][Full Text] [Related]
39. Transcriptional response to fluconazole and amphotericin B in Candida albicans biofilms.
Nailis H; Vandenbosch D; Deforce D; Nelis HJ; Coenye T
Res Microbiol; 2010 May; 161(4):284-92. PubMed ID: 20170727
[TBL] [Abstract][Full Text] [Related]
40. Minimum inhibitory concentrations of amphotericin B, azoles and caspofungin against Candida species are reduced by farnesol.
Cordeiro RA; Teixeira CE; Brilhante RS; Castelo-Branco DS; Paiva MA; Giffoni Leite JJ; Lima DT; Monteiro AJ; Sidrim JJ; Rocha MF
Med Mycol; 2013 Jan; 51(1):53-9. PubMed ID: 22712455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
